Přejít na obsah
ABTABT
Zpět na vyhledávání
ABT
ABTNYSE

Abbott Laboratories

Healthcare•United States
101,07 US$
-2,42 US$ (-2,34 %)

Tažením v grafu vyberte úsek a zobrazí se procentuální změna.Tažením dvěma prsty vyberte úsek a zobrazí se procentuální změna.

Kapitálová struktura

Tržní kapitalizace
174,89 mld. US$
Enterprise Value
202,66 mld. US$
Hotovost
5,6 mld. US$
Celkový dluh
32,72 mld. US$
Čistý dluh
27,12 mld. US$

Valuace (TTM)

P/E
33,47×
P/E (fwd)
16,66×
P/FCF
22,35×
FCF výnos
4,47 %
EV/EBITDA
17,35×
P/S
—
P/B
3,42×
Beta
0,59

Marže (TTM)

Hrubá marže
56,85 %
EBITDA marže
25,07 %
Provozní marže
14,71 %
Čistá marže
11,65 %
FCF marže
16,80 %

Ziskovost a růst

ROE (rentabilita kapitálu)
10,58 %
Růst tržeb (YoY)
13,00 %
Růst zisku (YoY)
-47,50 %

Dividenda

Dividendový výnos
2,44 %
Roční dividenda
2,52 US$
Výplatní poměr
78,96 %
Datum ex-dividendy
2026-10-15

52týdenní rozpětí

81,97 US$135,45 US$
Aktuální
101,07 US$
Pozice v pásmu
36 %
Nad ročním minimem
+23,30 %
Pod ročním maximem
-25,38 %

Cena v kontextu

-28,55 %od historického maxima
Historické maximum
141,46 US$
Datum maxima
27. 12. 2021
Zpět na maximum
+39,96 %
200denní průměr
104,87 US$
Odchylka od průměru
-3,62 %

O společnosti

Web

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Vedení společnosti

Mr. Robert B. Ford
Generální ředitel (CEO)
  • Mr. Philip P. BoudreauCFO & Executive VP of Finance
  • Mr. Daniel Gesua Sive SalvadoriExecutive VP and Group President of Established Pharmaceuticals & Nutritional Products
  • Mr. Christopher J. ScogginsExecutive Vice President of Diabetes Care
  • Ms. Lisa D. EarnhardtExecutive VP & Group President of Medical Devices
  • Ms. Sabina EwingSenior VP of Business & Technology Services and Chief Information Officer
  • Mr. Michael ComillaVice President of Investor Relations.
  • Erica L. BattagliaVP and Chief Ethics & Compliance Officer
  • Ms. Elizabeth C. CushmanExecutive VP, General Counsel & Secretary
  • Ms. Melissa BrotzSenior Vice President of Global Marketing & External Affairs